Patients were randomly allocated to receive subcutaneous injections of semaglutide 2.4 mg, semaglutide 1.0 mg, or placebo once a week for 68 weeks, along with lifestyle intervention
More recently, a survey conducted in August 2025 found that nearly 12% of Americans had used a GLP-1 drug for weight loss at some point, with GLP-1 sales projected to reach $100 billion by 2030
Weight loss can be harder for women over 40 due to hormonal shifts, sleep disruption, and gradual muscle loss
10.1016/j.jep.2024.117874 137 ZhaoF.HuangY.JiJ.LiuX.LiX.ZouL.et al (2024)
For R&D strategy teams, the implication is direct: when choosing between a small-molecule and biologic approach to a therapeutic target, the IRAs clock differential now adds a four-year premium to the biologic NPV that must be factored explicitly into portfolio prioritization
Don't risk using degraded peptides